To the Editor: In the CARD trial reported by de Wit et al. (Dec. 26 issue),(1) 255 patients with metastatic castration-resistant prostate cancer who had previously received docetaxel and who had disease progression while receiving abiraterone or enzalutamide were randomly assigned to cabazitaxel or the other androgen-signaling-targeted inhibitor. Cabazitaxel significantly improved several clinical outcomes, including imaging-based progression-free survival and overall survival, as compared with hormonal treatment. This trial represents an important step forward in the understanding of appropriate advanced treatment in patients with metastatic castration-resistant prostate cancer. However, it should be noted that 61.2% of the patients received hormonal treatment . . .
Cabazitaxel in metastatic prostate cancer / Di Nunno V.; Mollica V.; Massari F.; De Wit R.; De Bono J.; Castellano D.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - ELETTRONICO. - 382:13(2020), pp. 1286-1286. [10.1056/NEJMc2000990]
Cabazitaxel in metastatic prostate cancer
Di Nunno V.;Mollica V.;Massari F.;
2020
Abstract
To the Editor: In the CARD trial reported by de Wit et al. (Dec. 26 issue),(1) 255 patients with metastatic castration-resistant prostate cancer who had previously received docetaxel and who had disease progression while receiving abiraterone or enzalutamide were randomly assigned to cabazitaxel or the other androgen-signaling-targeted inhibitor. Cabazitaxel significantly improved several clinical outcomes, including imaging-based progression-free survival and overall survival, as compared with hormonal treatment. This trial represents an important step forward in the understanding of appropriate advanced treatment in patients with metastatic castration-resistant prostate cancer. However, it should be noted that 61.2% of the patients received hormonal treatment . . .I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
